JPWO2019166928A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019166928A5 JPWO2019166928A5 JP2020544823A JP2020544823A JPWO2019166928A5 JP WO2019166928 A5 JPWO2019166928 A5 JP WO2019166928A5 JP 2020544823 A JP2020544823 A JP 2020544823A JP 2020544823 A JP2020544823 A JP 2020544823A JP WO2019166928 A5 JPWO2019166928 A5 JP WO2019166928A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- combination
- pharmaceutically acceptable
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940125763 bromodomain inhibitor Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 8
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 7
- 229960004390 palbociclib Drugs 0.000 claims description 7
- RSMYFSPOTCDHHJ-GOSISDBHSA-N (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)piperidin-4-yl]phenoxy]ethyl]-1,3-dimethylpiperazin-2-one Chemical compound COC1=NN=C2N1N=C(C=C2)N1CCC(CC1)C1=CC=C(OCCN2[C@@H](C(N(CC2)C)=O)C)C=C1 RSMYFSPOTCDHHJ-GOSISDBHSA-N 0.000 claims description 6
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 claims description 6
- 101710126816 Bromodomain-containing protein 2 Proteins 0.000 claims description 6
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims description 6
- 101710126815 Bromodomain-containing protein 4 Proteins 0.000 claims description 6
- 102000001805 Bromodomains Human genes 0.000 claims description 5
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 claims description 4
- 101710126814 Bromodomain-containing protein 3 Proteins 0.000 claims description 4
- 108091005575 Bromodomain-containing proteins Proteins 0.000 claims description 4
- 239000011885 synergistic combination Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002381 testicular Effects 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 7
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 5
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 5
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108050009021 Bromodomains Proteins 0.000 description 1
- 229940083347 Cyclin-dependent kinase 4 inhibitor Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635916P | 2018-02-27 | 2018-02-27 | |
| US62/635,916 | 2018-02-27 | ||
| US201962796223P | 2019-01-24 | 2019-01-24 | |
| US62/796,223 | 2019-01-24 | ||
| PCT/IB2019/051462 WO2019166928A1 (en) | 2018-02-27 | 2019-02-22 | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021514975A JP2021514975A (ja) | 2021-06-17 |
| JP2021514975A5 JP2021514975A5 (https=) | 2022-03-02 |
| JPWO2019166928A5 true JPWO2019166928A5 (https=) | 2022-03-02 |
Family
ID=65904498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544823A Pending JP2021514975A (ja) | 2018-02-27 | 2019-02-22 | サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200405809A1 (https=) |
| EP (1) | EP3758753A1 (https=) |
| JP (1) | JP2021514975A (https=) |
| CA (1) | CA3092003A1 (https=) |
| WO (1) | WO2019166928A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI841598B (zh) * | 2018-09-13 | 2024-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療雌激素受體陽性乳癌之組合療法 |
| TW202126638A (zh) * | 2019-09-30 | 2021-07-16 | 日商協和麒麟股份有限公司 | Bet分解劑 |
| CA3166741A1 (en) * | 2020-01-09 | 2021-07-15 | Astrazeneca Ab | Combination therapy for treating cancer |
| JP7579564B2 (ja) | 2020-10-28 | 2024-11-08 | 国立大学法人金沢大学 | Ｒｂ１陽性癌の治療用医薬組成物及びキット |
| CN117100868A (zh) * | 2023-10-10 | 2023-11-24 | 复旦大学 | 溶瘤单纯疱疹病毒oHSV联合NETosis抑制剂在制备抗肿瘤药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| ES2251677T3 (es) | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| BRPI0716880A2 (pt) | 2006-09-08 | 2013-10-15 | Pfizer Prod Inc | Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| US9073878B2 (en) * | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| SI2958916T1 (sl) | 2013-02-21 | 2018-11-30 | Pfizer Inc. | Trdne oblike selektivnih zaviralcev CDK4/6 |
| CA2929652A1 (en) * | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| EP3215135B1 (en) * | 2014-11-07 | 2020-05-13 | Tolero Pharmaceuticals, Inc. | Methods to target transcriptional control at super-enhancer regions |
| MX376083B (es) | 2015-06-04 | 2025-03-07 | Pfizer | Formas de dosificacion solidas de palbociclib. |
-
2019
- 2019-02-22 EP EP19713199.8A patent/EP3758753A1/en not_active Withdrawn
- 2019-02-22 US US16/975,837 patent/US20200405809A1/en not_active Abandoned
- 2019-02-22 CA CA3092003A patent/CA3092003A1/en not_active Abandoned
- 2019-02-22 JP JP2020544823A patent/JP2021514975A/ja active Pending
- 2019-02-22 WO PCT/IB2019/051462 patent/WO2019166928A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021514975A5 (https=) | ||
| Ehsanian et al. | Beyond DNA binding-a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers | |
| EP3066101B1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| NO20060307L (no) | Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet | |
| ATE307608T1 (de) | Kombination von doctaxel und rhumab her2 zür krebsbehandlung | |
| BR0110877A (pt) | Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer | |
| JP2006500346A5 (https=) | ||
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| BRPI0408005A (pt) | composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor | |
| NO20071512L (no) | Terapeutiske kombinasjoner omfattende poly(ADP-ribose)polymeraseinhibitor. | |
| IS6647A (is) | Kínasólínafleiður til að meðhöndla æxli | |
| NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
| CY1106259T1 (el) | Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο | |
| BRPI0517104A (pt) | tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico | |
| Anai et al. | Antitumor effect of fibrin glue containing temozolomide against malignant glioma | |
| DE60237993D1 (de) | Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs | |
| JPWO2019166928A5 (https=) | ||
| ATE353650T1 (de) | Kombinationstherapie zur behandlung von krebs | |
| BRPI0511800A (pt) | tratamento com irinotecano (cpt-11) e um inibidor de egfr | |
| CN109562097B (zh) | 穿心莲内酯治疗多发性硬化的进行形式 | |
| JPWO2021260111A5 (https=) | ||
| CA2531620A1 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
| BR0308293A (pt) | Terapia à base de estatina para aumentar a manutenção cognitiva |